Neoadjuvant therapy with intensity-modulated radiotherapy combined with S-1 for borderline-resectable pancreatic cancer.
Yusuke OkamuraRyuta NishitaiNaoya SasakiHitoshi ItoTakashi SakamotoYoshio ItokawaMasanori KusumotoYoshitaka NakaiToshihide YamaokaDai ManakaPublished in: Asia-Pacific journal of clinical oncology (2024)
NAC-IMRT showed outstanding clinical efficacy with acceptable tolerability in patients with BRPC, including geriatric patients.
Keyphrases
- locally advanced
- end stage renal disease
- newly diagnosed
- rectal cancer
- ejection fraction
- chronic kidney disease
- early stage
- transcription factor
- peritoneal dialysis
- radiation therapy
- prognostic factors
- lymph node
- squamous cell carcinoma
- open label
- clinical trial
- randomized controlled trial
- patient reported outcomes
- smoking cessation